| Phase II Study to Evaluate Safety and Efficacy of Cetuximab in Combination With XELOX for 12 Weeks Followed by Maintenance Treatment With Cetuximab Plus Capecitabine as First-line Treatment in Elderly Patients With Metastatic Colorectal Cancer. (NCT00531115) | Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD) | 2007-11-01 |
| RSHF in Colorectal Cancer (NCT01220063) | Institut Cancerologie de l'Ouest | 2007-10-19 |
| Phase 1b/2 Study of AMG 655 With mFOLFOX6 and Bevacizumab for First-Line Metastatic Colorectal Cancer (NCT00625651) | Amgen | 2007-10-01 |
| Intermittent Versus Continuous Tarceva Study (NCT01243047) | Chinese University of Hong Kong | 2007-09-01 |
| Study of IMC-11F8 in Participants With Colorectal Cancer (NCT00835185) | Eli Lilly and Company | 2007-08-01 |
| Irinotecan/Oxaliplatin/5-Fluorouracil/Leucovorin/Cetuximab As First Line Treatment In Colorectal Cancer (NCT00689624) | University Hospital of Crete | 2007-07-01 |
| Chemotherapy and Avastin Followed by Maintenance Treatment With Avastin +/- Tarceva (NCT00598156) | Lund University Hospital | 2007-06-01 |
| A Phase I/II Study of Cediranib (AZD2171) in Japanese Metastatic Colorectal Cancer Patients in Combination With FOLFOX (NCT00494221) | AstraZeneca | 2007-06-01 |
| Study Of FOLFIRI Chemotherapy With Or Without Sunitinib In Patients With Metastatic Colorectal Cancer (NCT00457691) | Pfizer | 2007-06-01 |
| Panitumumab Plus FOLFIRI in First-line Treatment of Metastatic Colorectal Cancer (NCT00508404) | Amgen | 2007-05-09 |
| Panitumumab in Combination With Irinotecan Chemotherapy as 2nd-line Therapy in Subjects With mCRC (NCT00475293) | Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD) | 2007-05-01 |
| Safety of Cetuximab and Oxaliplatin/5-FU/FA/Irinotecan in First-Line Treatment of Metastatic Colorectal Cancer (NCT00422773) | Technische Universität Dresden | 2007-01-01 |
| Evaluation of Contrast-enhanced Ultrasound Imaging for the Early Estimate of Bevacizumab Effect on Colorectal Cancer Liver Metastases (NCT00489697) | University Hospital, Tours | 2007-01-01 |
| Pre- and Postoperative Chemotherapy Including Bevacizumab in Potentially Curable Metastatic Colorectal Cancer (NCT00444041) | Austrian Society Of Surgical Oncology | 2007-01-01 |
| Pattern of Cell Death Following Neoadjuvant Therapy for Metastatic Colon Cancer (NCT00414492) | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 2006-12-01 |
| Panitumumab Regimen Evaluation in Colorectal Cancer to Estimate Primary Response to Treatment (NCT00411450) | Amgen | 2006-11-01 |
| Cediranib (AZD2171, RECENTIN™) in Addition to Chemotherapy in Patients With Untreated Metastatic Colorectal Cancer (NCT00399035) | AstraZeneca | 2006-11-01 |
| Tailored Treatment in Metastatic Colorectal Cancer (NCT00396487) | Vejle Hospital | 2006-11-01 |
| SPIRITT - Second-Line Panitumumab Irinotecan Treatment Trial (NCT00418938) | Amgen | 2006-11-01 |
| Phase II Efficacy Study of AZD6244 in Colorectal Cancer (NCT00514761) | AstraZeneca | 2006-09-01 |
| PRIME: Panitumumab Randomized Trial In Combination With Chemotherapy for Metastatic Colorectal Cancer to Determine Efficacy (NCT00364013) | Amgen | 2006-08-01 |
| Phase II Study of Bevacizumab, Capecitabine and Oxaliplatin in Colon Cancer (NCT00378066) | Asan Medical Center | 2006-08-01 |
| Comparison of Treatment Effect of Chemotherapy With Panitumumab to Chemotherapy Alone (NCT00339183) | Amgen | 2006-06-30 |
| Capecitabine and Oxaliplatin Plus Bevacizumab as Neoadjuvant Treatment for Untreated Unresectable Liver-only Metastases From Colorectal Cancer (NCT01022541) | Royal Marsden NHS Foundation Trust | 2006-06-01 |
| 1stline Study Capecitabine Administered on Continuous Way Plus Oxaliplatin&Bevacizumab Every 2weeks in Metastatic CCR. (NCT00345696) | Unidad Integral de Investigación en Oncología S.L. | 2006-06-01 |
| BAY 43-9006 Plus Cetuximab to Treat Colorectal Cancer (NCT00326495) | National Cancer Institute (NCI) | 2006-05-10 |
| Phase III Randomized Study of 5-FU, CoFactor, and Avastin vs. 5-FU, LV and Avastin for First-Line Colorectal Cancer. (NCT00337389) | Mast Therapeutics, Inc. | 2006-05-01 |
| IRIS Followed by mFOLFOX6 or the Reverse Sequence in Advanced Colorectal Cancer (NCT00316745) | Hokkaido Gastrointestinal Cancer Study Group | 2006-04-01 |
| Skin Toxicity Treatment in Metastatic Colorectal Cancer (mCRC) Patients Receiving Panitumumab + Irinotecan-based Therapy (NCT00332163) | Amgen | 2006-04-01 |
| Phase 2 Study of ABX-EGF (Panitumumab) in Japanese Subjects With M-colorectal Cancer (NCT00327119) | Amgen | 2006-04-01 |
| Capecitabine Plus Oxaliplatin Plus Bevacizumab as First-line Treatment in Elderly Patients With Metastatic Colorectal Cancer (NCT01024504) | Hellenic Oncology Research Group | 2006-03-01 |
| Validation Study of Linear Quantification of CD3+ Cells in Localized Colorectal Carcinomas (NCT02364024) | Federation Francophone de Cancerologie Digestive | 2005-11-01 |
| Cetuximab, Bevacizumab & 5FU/Leucovorin vs. Oxaliplatin, Bevacizumab & 5FU/Leucovorin in Metastatic Colorectal Cancer (NCT00252564) | US Oncology Research | 2005-09-01 |
| Safety and Efficacy of Folfox6 + Cetuximab Versus Folfiri +Cetuximab in Patients With Metastatic Colorectal Cancer (NCT00286130) | Central European Cooperative Oncology Group | 2005-07-01 |
| Toxicity/Benefit Ratio Optimization of Chemotherapy in Colorectal Cancer (CRC) Patients by Determination of Individual Genotypic Determinants (NCT00138060) | Institut de Recherche Clinique sur les Cancers et le Sang | 2005-06-01 |
| FLOX in Combination With Cetuximab in First-line Treatment of Colorectal Cancer (NCT00145314) | The Nordic Colorectal Cancer Biomodulation Group | 2005-05-01 |
| Cap/Iri Plus Cetuximab Compared to Cap/ox Plus Cetuximab in Patients With Metastatic Colorectal Cancer. (NCT00254137) | Ludwig-Maximilians - University of Munich | 2004-09-01 |
| Irinotecan, 5-Fluorouracil and Leucovorin With or Without Iressa in the Treatment of Metastatic Colorectal Cancer (NCT00233623) | AstraZeneca | 2004-07-01 |
| A Study of the Combination of Pemetrexed and Irinotecan Every Two Weeks in Metastatic Colorectal Cancer (NCT00191984) | Eli Lilly and Company | 2004-06-01 |
| Study of the Antitumor Activity of Capecitabine in Combination With Erlotinib in Patients With Metastatic Colorectal Cancer (NCT00459901) | Peter Kozuch | 2004-06-01 |
| Oxaliplatin, 5-FU and Leucovorin in Combination With Oral Capecitabine for Metastatic Colorectal Cancer (NCT00205322) | University of Wisconsin, Madison | 2004-04-01 |
| An Exploratory Pharmacogenomic Study of Monotherapy Erbitux in Subjects With Metastic Colorectal Cancer (NCT00207155) | Eli Lilly and Company | 2003-12-01 |
| A Phase I/II Study of IXO With Bevacizumab in Patients With Metastatic Colorectal Cancer (NCT00819754) | Ottawa Hospital Research Institute | 2003-11-01 |
| Study of Glutamine as Prophylaxis for Irinotecan Induced Diarrhea (NCT00255229) | AHS Cancer Control Alberta | 2002-12-01 |
| FOLFOXIRI Compared With FOLFIRI for Metastatic Colorectal Cancer (NCT01219920) | Gruppo Oncologico del Nord-Ovest | 2001-11-01 |
| Tumor-Pulsed Dendritic Cells Used as a Tumor Vaccine (NCT00176761) | University of Michigan Rogel Cancer Center | 2000-03-01 |
| Expanded Access of Onvansertib With FOLFIRI and Bevacizumab for the Second-Line Treatment of Participants With KRAS-Mutated Metastatic Colorectal Cancer (NCT04446793) | Cardiff Oncology | |
| Computer Assisted Early Detection of Liver Metastases From fMRI Maps (NCT00435097) | Hadassah Medical Organization | |
| Maintenance Chemotherapy for Metastatic Colorectal Carcinoma and Biological Marker (NCT02043821) | Beijing Chao Yang Hospital | |